Needham analyst Matthew Shea has maintained their neutral stance on AGL stock, giving a Hold rating on March 10.
Matthew Shea’s rating is based on a combination of factors including the recent challenges Agilon Health is facing and the improvements they are implementing for 2025. Despite the company’s strategic decisions that seem promising, there is uncertainty about their effectiveness as the results are yet to be reflected in the financial figures.
Investors are finding it difficult to interpret the current improvements due to the timing of when issues typically arise, which is usually in the latter half of the year. Shea acknowledges the potential in Agilon Health’s plans but maintains a Hold rating until there is clearer evidence of success in their financial performance.
In another report released on March 10, Bernstein also maintained a Hold rating on the stock with a $3.30 price target.